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Mutations in the von Hippel–Lindau (VHL) gene are pathogenic in VHL disease, congenital polycythaemia and
clear cell renal carcinoma (ccRCC). pVHL forms a ternary complex with elongin C and elongin B, critical for pVHL
stability and function, which interacts with Cullin-2 and RING-box protein 1 to target hypoxia-inducible factor for
polyubiquitination and proteasomal degradation. We describe a comprehensive database of missense VHL
mutations linked to experimental and clinical data. We use predictions from in silico tools to link the functional
effects of missenseVHLmutations to phenotype. The risk of ccRCC in VHL disease is linked to the degree of de-
stabilization resulting from missense mutations. An optimized binary classification system (symphony), which
integrates predictions from five in silico methods, can predict the risk of ccRCC associated with VHLmissense
mutations withhighsensitivityandspecificity.Weusesymphony to generate predictions for risk ofccRCC forall
possible VHL missense mutations and present these predictions, in association with clinical and experimental
data, in a publically available, searchable web server.
INTRODUCTION
von Hippel–Lindau (VHL) disease is an autosomal dominant
syndrome associated with multiple tumours including retinal
and central nervous system (CNS) haemangioblastoma, clear
cell renal carcinoma (ccRCC) and phaeochromocytoma (PCC),
which results from mutations in the VHL gene (reviewed in 1).
Over 1000 VHL mutations including .900 VHL kindreds are
documented (2,3). Fifty-two percent of VHL disease mutations
are missense (3), which are broadly distributed throughout the
gene. In addition, inheritance of certain VHL mutations in an
autosomal recessive fashion, with either homozygous or com-
pound heterozygous alleles, can lead to congenital polycythae-
mias (4–12). Germline VHL mutations also account for up to
50% of patients with apparently isolated familial PCC and 11%
of patients with an apparently sporadic PCC (13,14).
The canonical VHL protein product, pVHL isoform 1
(pVHL30), has two structurally different domains: an N-terminal
53 amino acid disordered domain not needed for tumour suppres-
sion and a C-terminal ordered domain consisting of an a-helical
domain (residues 155–192) and a mainly b-sheet domain (resi-
dues 63–154 and 193–204). pVHL forms a ternary complex
with the elongin C and elongin B proteins (15–17) (henceforth
VCB complex) that is critical for pVHL stability (18) and func-
tion. Mutations that affect pVHL-binding residues in elongin C
have been described in ccRCC (19), supporting the hypothesis
that the tumourigenic effects ofVHLmutations relate to dysfunc-
tion of the VCB complex. Thus, the entire VCB complex should
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be considered a single entity when assessing the structural and
functional effects of VHL mutations. The VCB complex nucle-
ates a complex containing Cullin-2 and RING-box protein 1
(16,20–23), which targets prolyl-hydroxylated hypoxia-
inducible factors (HIFs) for polyubiquitination and proteasomal
degradation (24,25). pVHL also has less well-characterized
HIF-independent functions.
VHL disease is classified into Type 1 or Type 2 depending on
the presence of PCC. In Type 1 disease the risk of PCC is low. In
Type 2 disease, accounting for up to 20% ofVHLkindreds is sub-
divided into: (2A) PCCs and other typical VHL disease manifes-
tations but low risk of ccRCC, (2B) PCCs and other typical VHL
disease manifestations including ccRCC and (2C) PCCs only. A
major limitation of this classification is that, due to the variability
of expression in VHL disease, accurate classification can only be
made in large kindreds. Furthermore, its use in assisting clinical
management is limited since a family may move from one
subtype to another. Most patients with truncating mutations or
exon deletions have Type 1 disease while kindreds with Type
2 disease usually have a missense mutation.
Experimental data support diverse effects for missense VHL
mutations on both HIF-dependent and HIF-independent pVHL
functions (Supplementary Material, Table S1). In vitromodelling
of naturally occurring mutations suggests (1) a correlation
between the risk of haemangioblastoma and the ability of a VHL
mutation to impair HIF regulation and (2) the risk of developing
ccRCC in VHL disease is linked to the degree to which HIF
activity is compromised (26,27). In contrast, certain Type 2C
VHL disease mutations retain their ability to downregulate
HIFa (26,27). Nonsense and frameshift mutations may have a
higher risk of ccRCC and haemangioblastomas than missense
mutations (28–30). Allelic heterogeneity and genetic modifiers
may influence the phenotypicvariabilityofVHL disease (31–33).
Somatic biallelic inactivation ofVHL also occurs in the major-
ity of sporadic ccRCCs (34–37). Nearly 250 different missense
mutations (32%) have been described in sporadic ccRCC (38).
Numerous studies have investigated with conflicting results
whether functional loss of VHL or the type of VHL mutation
may influence prognosis in ccRCCs (reviewed in 39).
Several different computational approaches to study and
predict the effects of missense mutations on protein structures
have been proposed (40–47). The methods require either se-
quence or structural information and present different limita-
tions, their performance depending on the impact on structural
stability or intermolecular interactions of the mutation;
methods are often complementary in approach to others (43)
implying that overall prediction quality could be improved by
combining different computational methods. pVHL poses several
unusual challenges to computational models: (i) it forms part
of a multi-subunit complex where folding is concerted with
assembly, (ii) the inter-subunit contacts predominantly involve
hydrogen bonding and (iii) it has a small hydrophobic core and
a significant portion of the stabilization comes from hydrogen-
bonding interactions (20).
Here we describe an integrated computational approach, built
upon a comprehensive database of missense VHL mutations
linked to experimental and clinical data. We present an optimized
predictive model (named symphony) that integrates predictions
from in silico models. Predictions both link the functional effects
of missense VHL mutations to phenotype and classify ccRCC
risk with high sensitivity and specificity. Our observations empha-
size: first, the importance of structural knowledge to delineate
mechanisms of disease; subtle structural and functional changes
resulting from missense mutations through multiple mechanisms
can be related to different phenotypes in VHL disease. Secondly,
they highlight the success of combining diverse yet complemen-
tary computational approaches to obtain a robust disease predictor
for complex proteins such as pVHL. We use symphony to generate
predictions for risk of ccRCC for all possible VHL mutations and
present these predictions, in association with clinical and experi-
mental data, in a publically available, searchable website.
RESULTS
Development of an integrated in silico workflow
We first constructed a comprehensive database of mutations in
VHL annotated with the available experimental and phenotypic
data (Supplementary Material, Table S2A). We established an
in silico workflow (i) to predict the quantitative impact of muta-
tions on stability and affinity of the VCB complex and (ii) to cor-
relate mutation effects with risk of ccRCC. To achieve the latter,
the predictions together with the compiled database (Supple-
mentary Material, Table S2A) were used as evidence to train
and test a binary classifier (which we named symphony) that
outputs the predicted risk of ccRCC according to Figure 1.
We developed new computational strategies that predict
changes in protein stability and protein–protein affinity.
We have previously shown that combining computational
methods based on different protein descriptors can lead to a pre-
dictor that performs better overall (43). Here we combine five
in silico methods, which consider different information regard-
ing short-/long-range structural ordering, side-chain interactions
and stability, evolutionary conservation of physicochemical
properties and protein–protein interactions. Mutation Cutoff
Scanning Matrix (mCSM) (43) (http://structure.bioc.cam.ac.uk/
mcsm) is based on the cutoff scanning matrix (CSM) concept and
relies on graph-based structural signatures (50,51). It is a protein
structural signature originally proposed and successfully used in
protein function prediction and structural classification tasks; it
has been recently extended and applied to large-scale receptor-
based protein ligand prediction. Site-directed mutator (SDM;
http://mordred.bioc.cam.ac.uk/~sdm/sdm.php) (44,45) uses
knowledge of structures of proteins where amino acid replace-
ments are tolerated within families of homologues over evolu-
tionary time. MOSST predictions (http://www.biomedcentral.
com/1471-2105/12/122/additional, last accessed on 19 July
2014) are based on evolutionary and functional information
obtained from conservation rules of physicochemical properties
of amino acids in a protein family (42). PoPMuSiC (40) (http://
http://babylone.ulb.ac.be/popmusic/) relies on statistical poten-
tials to represent different protein descriptors and elucidate cor-
relations between them. This has been adapted as a predictor of
binding free energy changes in protein–protein complexes due
to single-point mutations in the BeAtMuSiC method (http://
http://babylone.ulb.ac.be/beatmusic/) (40,41). In order to gener-
ate a consensus prediction exploiting the diversities of each
method, we combined the results obtained by each category of
method in an optimized predictor using a regression model
tree (48). This resulted in two combined output predictions: (i)
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combined predicted stability change (CPSC) and (ii) protein–
protein affinity change (PPAC).
VHL disease ccRCC-associated mutations are significantly
more destabilizing than mutations not associated
with ccRCC
Mutations of surface residues were less common in ccRCC-
associated than non-ccRCC-associated VHL disease (16.1
versus 34.4%, P ¼ 0.0353; Supplementary Material, Table S3;
Fig. 2). Solvent-exposed mutations would in general be expected
to be less destabilizing than buried mutations at interfaces or
within the protein core. Consistent with this, predicted CPSCs
for ccRCC-associated mutations were significantly more desta-
bilizing than those for non-ccRCC-associated mutations, irre-
spective of the groups of mutations included in the analysis
(Supplementary Material, Table S4).
On subgroup analysis, predicted CPSCs for ccRCC-
associated Type 2 mutations were significantly more destabiliz-
ing than those for non-ccRCC-associated Type 2 mutations
(P ¼ 0.0043; Supplementary Material, Table S4). There was
no difference in predicted CPSC between Type 1 mutations asso-
ciated and not associated with ccRCC, though this may simply
reflect the small number of mutations in the latter cohort (n ¼ 7).
There was no difference in predicted stability change
between Type 1 and Type 2 mutations
Although Type 1 mutations were less likely to involve surface
residues than Type 2 mutations (10.2 versus 29.6%,
P ¼ 0.0113), there was no difference in CPSC (P ¼ 0.395) or
in the proportion of mutations which involved interface residues
in Type 1 versus Type 2 VHL disease (P ¼ 0.353, Fig. 2; Supple-
mentary Material, Table S5).
Interface residues (Supplementary Material,
Tables S3, S5 and S6)
Type 1 missense mutations were more likely to disrupt the HIF
interface than Type 2 mutations (P ¼ 0.0014). In contrast to pre-
vious findings (52), we found no difference in the proportion of
mutations predicted to disrupt elongin C binding between Type 1
(11/49, 22%) and Type 2 missense mutations (23/72, 32%,
P ¼ 0.254) and found no particular association of ccRCC with
specific pVHL regions.
Germline mutations associated only
with phaeochromocytomas
Seven Type 2C mutations are listed in the literature; one, L188V,
is also associated with hereditary polycythaemia. We have not
included R64P, R161Q, R167G, G93S and C162Y as Type 2C
mutations, since they have been reclassified as Type 2B or
Type 1 mutations in different kindreds, suggesting a variability
of expression influenced by factors other than genotype. A rep-
resentative list of germline VHL mutations associated with iso-
lated PCCs is shown in Supplementary Material, Table S2B
(13,14,53–55). We analysed only those germline mutations
that are exclusively associated with PCCs germline mutations
associated only with phaeochromocytomas (GMEPs; n ¼ 26;
Figure 1. Workflow for predicting ccRCC risk for missense mutations in VHL. For a given mutation, computational methods from different paradigms are used to
quantitatively assess its effects on protein stability and protein interactions with other proteins or ligands, all of which could affect function. These results are combined
in optimized predictors via a regression model tree (using the M5 algorithm) (48) as a way to leverage the best of each method as well as to generate a consensus
prediction. Experimental data were used to label each mutation in a training set according to ccRCC risk. The stability and affinity predictions are then used as evidence
to train and test a binary classifier, using the ensemble learning method Random Forest (49), that outputs the predicted risk of ccRCC in a binary classification scheme
(high or low risk). We named this integrated computational approach symphony.
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20 PCC-associated germline mutations and six Type 2C VHL
disease mutations).
GMEPs form a diverse group in terms of location within the
structure of pVHL and predicted effects on the stability of the
VCB complex. Predictions range from severely destabilizing to
non-destabilizing (CPSC ranged from 1.32 to 24.797). Experi-
mental data support diverse HIFa-regulation functional effects
for these mutations (Supplementary Material, Table S7). There
was no difference in amino acid exposure classification (Supple-
mentary Material, Tables S3 and S5) or CPSC (Supplementary
Material,Table S4) betweenGMEPS andVHL diseasemutations.
Polycythaemia mutations are significantly more stable
than all other VHLmutation groups
To date, 18 VHL mutations have been described in patients with
hereditary polycythaemias (Supplementary Material, Table S8).
Fourteen have never been associated with VHL disease or PCC.
However, L188V is a Type 2C mutation and G104V, V130I and
Y175C have been described as germline mutations associated
with PCC; these mutations were excluded from subsequent ana-
lyses. When analysed as a group, CPSCs for hereditary polycy-
thaemia VHL mutations are significantly less destabilizing than
any other group of mutations, including non-ccRCC-associated
VHL disease mutations (Supplementary Material, Table S4).
Sensitive prediction of ccRCC risk for germline
VHLmutations
CPSC and PPAC predictions were combined to classify each
mutation as ‘high risk’ or ‘low risk’ of association with
ccRCC. For the 121 VHL mutations included in the training
set, symphony was 100% sensitive and 98% specific at predict-
ing risk of ccRCC (Supplementary Material, Table S9A). We
then looked at symphony’s predictions for mutations included
in both the training set and the test set. The predictions for the
162 germline VHL mutations are shown in Supplementary Ma-
terial, Tables S2C and S9B and Figure 3. Of the 90 high-risk
mutations, 84 (93.3%) had a diagnosis of VHL disease. 14 of
14 germline mutations associated only with hereditary polycy-
thaemia were predicted to be low risk. The binary classifications
for the 121 mutations associated with VHL disease are shown in
Supplementary Material, Table S10.
For VHL disease mutations, the sensitivity of symphony in
terms of predicting risk of ccRCC in VHL disease was 100%
(95% CI 94.2–100%) and its specificity was 81.3% (95% CI
63.6–92.8%). Six VHL disease mutations were predicted high
risk but have not yet been associated with ccRCC in VHL
disease (Supplementary Material, Table S11). Of these, five
have been described in sporadic ccRCC and some have experi-
mental data suggesting that the resulting pVHL mutants are
defective in HIFa-regulation. We suggest that patients with
these germline mutations are at risk of ccRCC.
The ‘Sorting Tolerant From Intolerant’ (SIFT) algorithm
(56) is commonly used to predict whether a single amino acid
substitution affects protein function. SIFT predictions for
mutations included in our training set are shown in Supplemen-
tary Material, Table S9C. The sensitivity (82.3%, 95% CI
70.5–90.8%) and specificity (54.2%, 95% CI 40.8–67.3%)
of SIFT was significantly lower than that of symphony.
Eleven high-risk mutations were predicted to be tolerated by
SIFT.
Figure 2.Exposure classification of mutations in different categories of disease. Type 2 mutations are more likely to involve surface residues than Type 1 mutations.
ccRCC-associated VHL disease mutations are less likely to involve surface residues than non-ccRCC-associated VHL disease mutations. A high proportion of
polycythaemia-associated mutations involves surface residues. Statistical significance (P , 0.05) indicated by asterisk.Inter., interface; Surf., surface; W/O, without.
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Predicting ccRCC risk for somatic VHLmutations
Two hundred and fifteen somatic VHL mutations are listed on
COSMIC (38) at the time of writing. Of these, 186 have been
described in sporadic ccRCC and 29 have only been described
in tumours other than ccRCC (Supplementary Material, Tables
S2A and S12). The prediction summary for ccRCC risk in spor-
adic tumours is shown in Supplementary Material, Table S13
and Figure 4.
Of the 215 somatic mutations, 124 (58%) were predicted
high risk and 91 (42%) low risk (Supplementary Material,
Table S13). Seventy-three of 186 (39%) of somatic ccRCC mis-
sense mutations were predicted to be low risk. The proportion of
high-risk mutations is significantly higher for mutations
described several times in sporadic disease compared with
those described only once and is significantly higher in sporadic
ccRCC compared with other somatic tumour types (61 versus
38%, P ¼ 0.0207; Supplementary Material, Table S13; Fig. 4).
Fifty-three percent of somatic ccRCC high-risk mutations have
also been described in VHL disease (and of these 75% have def-
initely been associated with ccRCC), compared with only 21% of
low-risk mutations (none of which have definitely been asso-
ciated with ccRCC) (P, 0.0001; Supplementary Material,
Table S14).
For mutations reported more than once in sporadic ccRCC,
62% of the high-risk mutations have been associated with VHL
disease, compared with 26% of the low-risk mutations
(P, 0.0001; Supplementary Material, Table S14 and Fig. S2).
For somatic mutations reported only once in ccRCC or in other
tumour types,only38% of the high-riskmutations havebeen asso-
ciated with VHL disease, compared with 18% of the low-risk
mutations (P ¼ 0.0132; Supplementary Material, Table S14).
Figure3.Binary classification of ccRCC risk for germlineVHLmutations associated with different phenotypes. High-risk mutations were more likely to be associated
with VHL disease than low-risk mutations. All ccRCC-associated VHL disease mutations were high risk. All polycythaemia-associated mutations were low risk.
Statistical significance (P, 0.05) indicated by asterix. w/o, without.
Figure 4. Predictions for risk of ccRCC in sporadic tumours. The proportion of high-risk mutations is significantly higher for mutations which have been described
several times in sporadic disease compared with those that have been described only once and is significantly higher in sporadic ccRCC compared with other somatic
tumour types.
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Predicted ccRCC risk for VHLmutations investigated
experimentally
A review of the literature revealed 65 missense VHL mutations
with measured experimental effects on HIFa regulation. These
experimental settings include non-standardized biophysical
and biochemical data in addition to cell culture studies using
cell lines that may express HIF1a, HIF2a or both. This explains
to some extent why different studies report different effects for
the same mutation. For example, pVHLR167Q has been reported
to be defective in HIFa regulation in some studies but similar to
wild type (WT) in others. Similarly, some pVHL mutants have
been reported to have different effects on HIF1a and HIF2a
which would not be detected in studies only looking at the
effect on one HIFa isoform. The balance of evidence suggests
that while HIF2a is an oncogene in ccRCC pathogenesis,
HIF1a may act as a tumour suppressor (57).
With these caveats, 15 mutations were predicted to be low risk
but are reported to be defective in HIFa regulation experimental-
ly (Supplementary Material, Table S18). None of these muta-
tions have been described in VHL disease associated with
ccRCC, suggesting that, in many cases, the extent of dysregula-
tion of HIFa seen in experimental systems may not be enough for
tumourigenesis. Paradoxically, D121Y and L153P have both
been described several times in sporadic ccRCC and are reported
to be defective in HIFa regulation, suggesting that in these cases
our low-risk prediction may be incorrect. Five mutations were
predicted to be high risk but have been reported to regulate
HIFa similarly to WT VHL in experimental systems. Four of
these (S80N, P81S, T157I and I180V) have all been described
in VHL disease associated with ccRCC suggesting the mutations
are high-risk despite appearing to regulate HIFa normally under
certain experimental conditions. In certain situations, our predic-
tions thus seem more sensitive than experimental data regarding
HIFa regulation in terms of determining the probable pathogenic
effect of a mutation. A finer structure–function analysis of
pVHL could shed light on these incongruences between predic-
tion, experiments and disease manifestation.
Development of a publically available web server
We use symphony to generate predictions for risk of ccRCC for
all possible VHL mutations. We present these predictions, in as-
sociation with clinical and experimental data, in a publically
available, searchable web server which can be freely accessed
by research groups worldwide (http://structure.bioc.cam.ac.uk/
symphony).
Linking predictions to clinicopathological features
in cohort of patients with sporadic ccRCC
Previously, we have presented the results of targeted sequencing
of VHL, BRCA1-associated protein-1 (BAP1), Polybromo 1
(PBRM1), SET domain containing 2 (SETD2) and lysine
(K)-specific demethylase 6A (KDM6A) on 132 ccRCCs and
matched normal tissues (58). Application of our integrated com-
putationalapproach tosomaticmissenseVHLmutations predicted
26 high-risk (76%) and 8 low-risk (24%) mutations. One mutation
(R58W) affects a residue that is not in the VHL crystal structure
and was excluded. There was no difference in clinicopathological
features between ccRCCs with predicted pathogenic VHL altera-
tions (high-risk missense mutations, nonsense or frameshift muta-
tions or promoter methylation) and those without predicted
pathogenic VHL alterations (including low-risk missense muta-
tions) (Supplementary Material, Table S15).
DISCUSSION
This work demonstrates the application of computational bio-
logical approaches to predict the effects of missense VHL
mutations in VHL disease, sporadic ccRCC and congenital poly-
cythaemia with potential clinical applications. We have created
a comprehensive and inclusive database of missense VHLmuta-
tions linked to experimental data and clinical phenotype. We
used this database to train and test an optimized binary classifi-
cation system (named symphony), which integrates predictions
from a variety of in silico methods and can predict the risk of
ccRCC associated with VHL missense mutations with high sen-
sitivity and specificity. We use symphony to generate predic-
tions for risk of ccRCC for all possible VHL mutations and
present these predictions, in association with clinical and experi-
mental data, in a publically available, searchable web server.
pVHL is an exemplary yet challenging protein to use as the
basis for development of an in silico predictive model; it forms
part of a ternary complex and, despite being small (213 amino
acids) we identified 294 unique missense mutations. Experimen-
tal data regarding the functional effects of 82 of these mutations
enabled us to validate the predictions from early in silicomodels,
this information was of particular use during development of
our final model and permitted us to identify and learn from
mutations which were incompletely assessed by various
in silico tools used independently. The association between
different mutations and distinct phenotypes in VHL disease
and VHL-associated congenital polycythaemias provided an ex-
cellent opportunity to identify the molecular basis of genotype–
phenotype correlations using bioinformatics tools. The novel
integrated strategy we have developed could easily be adapted
for other systems.
Phaeochromocytomas in VHL disease
GMEP mutations are broadly distributed throughout VHL and
the resulting amino acid changes are predicted to have diverse
effects on pVHL and the VCB complex; some, such as F119S,
are severely destabilizing hydrophobic core mutations; others,
such as D143Q, are minimally destabilizing surface mutations.
Experimental data report diverse effects with respect to HIFa
regulation for Type 2C VHL disease mutations (Supplementary
Material, Table S7). In contrast to previous less comprehensive
work (52), we found no evidence that mutations associated with
PCCs (Type 2) are more likely to disrupt interactions at the
elongin C interface than mutations not associated with PCCs
(Type 1). Only 8% of Type 2 mutations were predicted to directly
disrupt the pVHL-HIFa interface, compared with 33% of Type 1
mutations, suggesting that a direct disruption of HIFa binding
may not be necessary to cause PCCs and that an HIF-independent
mechanism underlies the pathogenesis of PCCs (further material
in Supplementary Material, Discussion).
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pVHL and hereditary polycythaemias
The most commonVHL polycythaemia mutation is the homozy-
gous C598T mutation, resulting in the amino acid substitution
R200W (4). Seventeen additional VHL variants (16 missense
and 1 nonsense) associated with congenital secondary polycy-
thaemia (CSP) have been described (Supplementary Material,
Table S8). Reports of tumour development in patients with
VHL-associated CSP are extremely rare (59,10), and a
knock-in R200W transgenic mouse exhibits polycythaemia
without tumour formation (60,61).
The molecular mechanism underlying VHL-associated CSPs
is debated (Supplementary Material, Table S16) and the lack
of tumourigenesis in VHL-associated CSPs is notable. Our
work demonstrates that mutations associated solely with heredi-
tary polycythaemias are significantly less destabilizing than all
other subgroups of disease-associated VHL mutations. CSP-
associated VHL mutations are distributed throughout VHL and
are not limited to the 3′ region ofVHL exon 3. Along with experi-
mental data summarized in Supplementary Material, Table S16,
this suggests that, in the majority of cases of VHL-associated
CSP, a combination of VHL-associated CSP mutations on both
VHL alleles, each of which independently results in minor
impairment of HIF2a activity, is sufficient to cause CSP but
insufficient to cause tumourigenesis.
Risk of ccRCC in VHL disease is linked to the degree
of destabilization resulting from missense mutations
There was no difference between the CPSC of Type 1 and Type 2
VHL disease mutations, or in the proportion of mutations which
involve interface residues, implying no clear functional differ-
ence between missense mutations described in Type 1 and
Type 2 VHL diseases. The description of at least 17 VHL mis-
sense mutations in both disease types supports this statement
(Supplementary Material, Table S2A). The only clear difference
between Type 1 and Type 2 mutations was a significantly lower
proportion of Type 2 mutations predicted to disrupt the HIFa
interface, and, in agreement with previous studies (29), a
higher prevalence of surface amino acid substitutions in Type
2 than Type 1 VHL disease.
In contrast, we report a clear difference between ccRCC- and
non-ccRCC-associated missense mutations; the risk of ccRCC
in VHL disease is significantly associated with the degree of
destabilization resulting from the mutations. This observation
is in agreement with experimental data linking risk of ccRCC
in VHL disease to the degree to which HIF activity is compro-
mised (26,27). Severely destabilizing mutations are expected
to dramatically impair the function of pVHL while less destabil-
izing mutations may allow partial preservation of pVHL’s func-
tion. Similarly, nonsense and frameshift mutations, which are
expected to knock-out most, if not all, of pVHL’s functionality,
have a higher risk of ccRCC and haemangioblastomas in VHL
disease than missense mutations (28–30). A small, earlier
study also associated ccRCC development in VHL disease
with a relatively high loss of structural stability in pVHL mis-
sense mutants (62).
Here we consider the effects of mutations that might destabil-
ize pVHL itself or its interactions within VCB (Fig. 5). The com-
putational approaches that we have used assess impacts of the
mutation on the conformation and direct interactions of the sub-
stituted amino acid on stability of the subunit and its interactions,
for example, through SDM, PoPMuSiC and BeAtMuSiC. They
also assess the importance of the more extended environment,
including depth of the amino acid in the core and its electrostatic
environment, which are implicit in mCSM and PoPMuSiC. We
suggest that diverse mechanisms of destabilization can result in
the same endpoint, namely disruption of pVHL’s ability to target
HIFa for ubiquitination and degradation, and that the degree of
dysfunction is closely associated with the degree of destabiliza-
tion resulting from a mutation. Alternatively, mutations such
as H115Y and S111R, which directly interfere with the
HIFa-hydroxyproline-binding site, may disrupt pVHL’s
ability to target HIFa for ubiquitination and degradation
without destabilizing the entire VCB complex; these mutations
may be associated with a low risk of PCC. Overall, our data
suggest that missense VHL mutations, which are drivers in
ccRCC pathogenesis, either destabilize the VCB complex as a
whole or directly affect the HIFa-hydroxyproline-binding site
(Fig. 6). In contrast to previous work, we found no suggestion
that disrupted interactions between pVHL and its binding part-
ners correlate with ccRCC-risk in VHL disease (52).
This model provides an explanation for the mechanism
whereby different mutations at the same position can be asso-
ciated with different phenotypes. For example, Y98H is a
Type 2A VHL disease mutation and is associated with a much
lower ccRCC risk in VHL disease than the Type 2B mutation
at the same residue, Y98N. This is reflected by a lower CPSC
for Y98N compared with Y98H. Experimental data have previ-
ously demonstrated Y98H to exhibit higher stability and greater
binding affinities for HIF1a compared with Y98N (63). Similar
findings are seen for Type 2A and Type 2B mutations at positions
G93, Y112, A149, R167, V170 and L188 (Supplementary
Material, Table S2A).
The data regarding the presence or absence of ccRCC in VHL
disease relates to kindreds only, rather than figures regarding the
proportion of patients with each mutation who developed
ccRCC. Thus, we were not able to discriminate between muta-
tions associated with a very high risk of ccRCC and mutations
which rarely cause ccRCC. However, our results suggest a gra-
dient effect of VHL missense mutations whereby the risk of
ccRCC increases roughly in proportion to the destabilizing
effect of the mutation.
Development of a binary classification system to predict the
risk of ccRCC associated with VHLmissense mutations
The disparate relationship between specific missenseVHLmuta-
tions and clinical phenotype in VHL disease and congenital
polycythaemias provides an excellent opportunity to develop a
sensitive and specific classifier to predict the risk of ccRCC in
VHL disease. The binary classifier we developed (symphony)
was trained using a dataset of mutations designated high risk
or low risk in terms of ccRCC pathogenesis based on experimen-
tal and clinical data. During training, our optimized model was
highly sensitive and specific and predicted the association of
high- and low-risk mutations with ccRCC with 100% accuracy.
Though its specificity was lower (81%) when looking at all VHL
disease mutations (i.e. including mutations from both the train-
ing and test sets) it is possible that the six mutations predicted
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Figure5.Wall-eye stereograms representing examples of the diverse mechanisms of the effects ofVHLmutations at the molecular level. (A) Mutations that disrupt the
HIFa-hydroxyproline-binding site. Mutations of H115 (A) cause loss of the tetracoordination of a buried water molecule, as well as the loss of an acceptor group for the
hydroxyl donor group in the HYP residue in hydroxylated HIF. They also disrupt up to four H-bonds within the buried hydrogen bond network that recognizes the HYP.
Mutations at S111 can cause the loss of the hydrogen donor for the HYP hydroxyl, with similar effects as above. Mutations at other depicted residues that participate in
the HYP hydrogen-bonding recognition network can have similar outcomes. Mutations at secondary HIFa-binding sites, such as the loop G104-R108 (B) could also
impair HIFa binding. Side chains of L562 and Y565 in HIF have not been represented for clarity in A. (B) Mutations that disrupt the hydrophobic core. Mutation in the
two VHL hydrophobic cores can disrupt VHL subunit conformation, such as mutations at F76 (beta domain, B) and V170 (alpha domain, C). (C) Mutations that disrupt
H-bond networks. Mutation of N78 (B) disrupts a significant buried H-bond network that stabilizes a region of VHL connecting two loops that are key for interaction
with HIF and elongin C. Mutation of residues that tightly interact in this network, such as S80 and T105 have the same effect. (D) Mutations that disrupt the conform-
ation of pVHL. Mutations of conserved glycines (e.g. G93, A) and prolines can directly disrupt and destabilize pVHL. (E) Mutations of residues within the elongin C-
and elongin B-binding sites. These mutations disrupt interaction with VHL-binding partners through disruption of H-bonding networks, such as mutations at R82 and
its neighbouring residues (B) and R161, or through disruption of hydrophobic cores formed by the interacting subunits in the VCB complex, such as mutations at V155,
L158, K159, C162, V165, V166, V170, L178 and L184 (C). (F) Mutations that disrupt long-range electrostatic interactions. These mutations can alter the charge
complementarity of the subunits in the VCB complex and destabilize protein–protein long- and short-range interaction, such as mutations at R79, R82, R107,
D121, D126 (B), K159 and D187 (C). In this figure, VHL is coloured in green, elongin C in cyan, elongin B in yellow, HIFa in magenta, Cullin 2 in pink-orange
and water oxygen atoms are represented as red balls.
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to be high risk that have not yet been associated with ccRCC in
VHL disease may be in the future.
In a blind test, symphony suggests that 39% of missense muta-
tions described in somatic ccRCC are low risk and may represent
passenger changes. Though this figure initially seems high it is
supported by several observations. First, the proportion of muta-
tions predicted to be high risk is significantly higher in mutations
described several times in sporadic disease compared with those
described only once and is significantly higher in sporadic
ccRCC compared with other somatic tumour types. Secondly,
53% of somatic ccRCC mutations predicted to be high risk
have been described in VHL disease (of these 67% have definite-
ly been associated with ccRCC) compared with only 21% of
mutations predicted to be low risk (none of which have definitely
been associated with ccRCC). Thirdly, the R200W mutation,
which has been clearly demonstrated to be non-tumourigenic
in terms of ccRCC pathogenesis, has been identified in two
cases of sporadic ccRCC thereby exemplifying the presence of
a low-risk VHL mutation in sporadic ccRCC. Finally, experi-
mental data for many of the predicted low-risk mutations
confirm that they appear to regulate HIFa similarly to WT VHL.
The ability to assess the risk of ccRCC associated with germ-
line VHL missense mutations in VHL disease may be clinically
useful, particularly since ccRCC is a significant cause of morbid-
ity and mortality (64,65). In sporadic ccRCC, as yet no clear as-
sociation between VHL mutation status and clinicopathological
Figure 6.A model to explain diverse phenotypes associated with VHL missense mutations. Frameshift/nonsense VHL mutations are likely to prevent formation of a
functional VCB complex and result in severe disruption of HIFa regulation, thereby explaining the high risk of ccRCC in Type 1 VHL disease. Missense VHLmuta-
tions may destabilize the VCB complex througha variety of mechanisms. Mutations which are severely destabilizing are likely to severely disrupt HIFa regulation and
are associated with a high risk of ccRCC. Less severely destabilizing mutations have a milder effect on HIFa regulation resulting in a lower risk of ccRCC. A few
mutations do not destabilize the VCB complex as a whole but instead directly disrupt the HIFa-hydroxyproline-binding site, thereby affecting HIFa regulation.
These mutations may be associated with a low risk of PCC. Some missense VHL mutations are not destabilizing and would not be predicted to affect the
HIFa-hydroxyproline-binding site and may represent passenger mutations.
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features has been identified (reviewed in 39). Sensitive and spe-
cific identification of passenger mutations which do not drive
tumour formation may allow identification, in large datasets,
of genotype–phenotype correlations for high-risk mutations
that have previously been concealed by the inclusion of passen-
ger mutations in analyses. Inactivation of VHL alone is not suf-
ficient to cause ccRCC (66,67) and recently, genomic
sequence analysis has identified several genes that are frequently
mutated in ccRCC. These includePBRM1,SETD2 andBAP1, all
of which lie on a relatively small, 43 Mb region of chromosome
3p and are, therefore, potentially deleted alongside VHL in
tumours with 3p loss. It is tempting to speculate that there may
be an association between the presence or absence of high-risk
VHL alterations and mutations in other driver genes (such as
PBRM1 and BAP1); assessment of these factors in combination
may be useful in predicting response to targeted therapies. This
concept could be investigated using the symphony web server
which presents predictions for all possible VHL mutations.
CONCLUSIONS
We have combined a variety of bioinformatics tools, each of
which uses a different methodology to independently predict
the effects of missense mutations with moderate efficacy, to
produce a combined model which can predict the risk of
ccRCC associated with missense VHL mutations with high sen-
sitivity and specificity. This study represents the most compre-
hensive analysis of VHL missense mutations to date. The
methodology we have developed is generic and transparent
and could easily be adapted for the study of different proteins
in other types of cancer. We have generated predictions for
risk of ccRCC for all possibleVHLmutations, presented in a pub-
lically available, searchable web server. This resource could
easily be utilized in analyses of sequencing data from large
patient cohorts, particularly from clinical trials of ccRCC
patients.
MATERIALS AND METHODS
Database of VHLmissense mutations
We compiled a comprehensive table of germline and somatic
VHL mutations (Supplementary Material, Table S2A) obtained
from numerous sources, including original articles, the Univer-
sal Mutation Database (UMD; http://www.umd.be/VHL/, last
accessed on 19 July 2014) (2) and the review article by
Nordstrom-O’Brien et al. (3). Details of mutations not included
in this review article were obtained from the original reference.
A list of somatic VHL mutations associated with sporadic
tumours was obtained from COSMIC (38). A representative
list of germline mutations described in non-syndromic PCC
was identified (13,14,53–55).
Accurate phenotype data are not publically available for all fa-
milial mutations, with many simply being classified as Type 1 or
Type 2 with no further details. Furthermore, a single mutation
may be classified differently in different kindreds, highlighting
the differential expression of VHL mutations between indivi-
duals. For the purpose of this study, mutations were subgrouped
depending on whether they have definitively been associated
with ccRCC or not. Mutations that have been associated with
ccRCC in at least one patient were documented as ccRCC asso-
ciated. If the clinical data associated with a mutation were in-
complete the association with ccRCC was documented as
‘unknown’. Mutations reported as both Type 1 and Type 2
were classified as Type 2 for the purpose of this study, since,
by definition, they have been associated with PCC in at least
one patient. Germline mutations associated with PCCs and no
other tumour types were only classed as Type 2C mutations if
they have been clearly associated with PCCs across more than
one generation. Germline mutations associated with PCCs
without a family history were classified as PCC-associated
germline mutations.
Experimentally defined functional effects of missense VHL
mutations were identified using the search terms ‘VHL’ and ‘Mu-
tation’ on PubMed.
Annotated datasets for machine learning
The primary aim of this work was to identify VHL mutations
likely to be pathogenic in ccRCC. We therefore compiled a
‘training’ set of 121 mutations: 62 ‘high-risk’ mutations identi-
fied as VHL disease mutations clearly associated with ccRCC;
and 59 so-called low-risk mutations, comprising (i) 6 mutations
described less than or equal to once in sporadic ccRCC with ex-
perimental data suggesting no functional effect resulting from
the mutation, (ii) 17 germline mutations described in association
with hereditary polycythaemia, (iii) 7 single-nucleotide poly-
morphisms not associated with sporadic or familial disease of
any kind as listed on NCBI (68) and (iv) 29 germline VHL
disease mutations with good quality clinical data documenting
no association with ccRCC. The test set of mutations compiled
173 mutations. These comprised: (i) 39 germline mutations asso-
ciated with VHL disease (all types), (ii) 1 germline mutation
associated with hereditary polycythaemia, (iii) 1 germline muta-
tion associated with CNS haemangioblastoma, (iv) 13 germline
mutations associated with PCCs, (v) 112 somatic mutations
associated with sporadic tumours (either ccRCC or other
tumour types) as listed on COSMIC (38) and (vi) 7 additional
mutations referenced in the literature without associated clinical
data. Details of all mutations are listed in the Supplementary
Material, Table S2A.
Predicting protein stability and PPAC upon mutation
Five computational methods were used to predict the effects of
missense mutations: (i) mCSM (43) (http://structure.bioc.
cam.ac.uk/mcsm), (ii) SDM (http://mordred.bioc.cam.ac.uk/
~sdm/sdm.php) (44,45), (iii) MOSST, (iv) PoPMuSiC (40)
(http://babylone.ulb.ac.be/popmusic/) and (v) BeAtMuSiC
(40,41) (http://babylone.ulb.ac.be/beatmusic/). In order to
improve overall accuracy and obtain a consensus prediction
from the several computational methods used, we combined
their results using regression trees, via an implementation of
the M5 model tree algorithm (48). Supplementary Material,
Figure S1 shows the obtained regression tree for the CPSC pre-
dictor. For PPAC the model tree obtained for the combined pre-
dictor only had one node that describes the following linear
model: DDG ¼ 0.758 × mCSM + 0.432 × BeAtMuSiC 2
0.035. The regression trees were trained using a diverse
dataset of 350 mutations with experimental thermodynamic
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data derived from the ProTherm (69) and SKEMPI (70) data-
bases and used in a blind test in a previous study (43). Supple-
mentary Material, Table S17 presents the Pearson’s correlation
coefficient obtained for each method as well as for the combin-
ation of them via regression trees.
Predicting risk of ccRCC in VHL disease
We developed a machine learning strategy to link the effects of
VHLmissense mutations to phenotype. Statistical analysis of the
CPSCs and combined predicted PPACs associated with mis-
sense mutations, linked to collated experimental data regarding
their functional effects and clinical phenotype, facilitated devel-
opment of a binary classifier that aims to relate the effects of mis-
sense mutations to risk of ccRCC; this was based on the finding
that mutations that are associated with ccRCC in VHL disease
tend to be more destabilizing than those that are not. The classi-
fier uses CPSC and PPAC predictions as evidence to train the
predictive model using the Random Forest algorithm (49), and
outputs the predicted risk of ccRCC in a binary classification
scheme (high or low risk).
Statistical analysis
All statistical analyses were performed using SPSS Statistics
20.0. Associations between a mutation group and predicted
DDGas were determined using unpaired Student’s t-test. Associ-
ation between a mutation group and exposure classification was
determined using: x2- test for categorical variables if .80% of
the expected counts are .5; Fisher’s exact test for categorical
variables if .20% of the expected counts are ,5. Unless indi-
cated P-values are two sided without adjustment for multiple
comparisons.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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